A new oral HER2-directed breast cancer therapy from Bayer AG, and its companion diagnostic from Thermo Fisher Scientific Inc., have been approved by the U.S. FDA. Hyrnuo (sevabertinib), a reversible ...
The FDA also approved Thermo Fisher's Oncomine Dx Target Test as a companion diagnostic to identify patients eligible for Hyrnuo.
FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for ...
The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...
Bayer (BAYRY) announced that the FDA has approved Hyrnuo, an oral, reversible, tyrosine kinase inhibitor for the treatment of adult patients with ...
BOSTON, Nov. 20, 2025 /PRNewswire/ -- TetraScience, the Scientific Data and AI Company, announced that Bayer AG will expand its deployment of TetraScience's Scientific Data Foundry across its ...
Bayer (BAYZF) stock is in focus as the FDA grants accelerated approval for the company's tumor drug Hyrnuo in non-squamous ...
The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...
The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer ...
Bayer’s sevabertinib picks up a second-line indication for HER2-mutated disease, joining Boehringer’s zongertinib on the US ...
Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback